Statistics

Total Visits

Views
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens64

Select a period of time:

Number of views in the range

Views
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens21

Views

Views
November 20254
December 20251
January 20261
February 20260
March 202612
April 20261
May 20262
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States14
France2
Argentina1
Côte d'Ivoire1
Hungary1
Tunisia1
Venezuela1
 

Top cities views

Views
San Jose10
Abidjan1
Ciudad Guayana1
North Bergen1
Río Gallegos1
Tunis1